Citations

Clear

815 citation(s) found for "Tang, Yu".

Incorporating multiple sets of eQTL weights into gene‐by‐environment interaction analysis identifies novel susceptibility loci for pancreatic cancer
Yang, Tianzhong , Tang, Hongwei, Olson, Sarah, Peterson, Gloria, Bracci, Paige M. , Gallinger, Steven , Hung, Rayjean J., Scélo, Ghislaine , Kurtz, Robert C. , Sund, Malin , Wareham, Nick, Li, Donghui , Wareham, Nicholas J. , Wei, Peng , Sund, Malin , Risch, Harvey A. , Hung, Rayjean J., Neale, Rachel Ε. , Duell, Eric J. , Khaw, Kay‐Tee , Severi, Gianluca , Amos, Christopher I. , Wei, Peng

Mayo Clinic

Genetic Epidemiology | August 11, 2020 | Volume: 44 | Issue: 8 | Pages: 880-892

10.1002/gepi.22348 | PMID 32779232 Get It

AbstractIt is of great scientific interest to identify interactions between genetic variants and environmental exposures that may modify the risk of complex diseases. However, larger sample sizes are usually required to detect gene‐by‐environment interaction (G × E) than required to detect genetic main association effects. To boost the statistical power and improve the understanding of the underlying molecular mechanisms, we incorporate functional genomics information, specifically, expression quantitative trait loci (eQTLs), into a data‐adaptive G × E test, called aGEw. This test adaptively chooses the best eQTL weights from multiple tissues and provides an extra layer of weighting at the genetic variant level. Extensive simulations show that the aGEw test can control the Type 1 error rate, and the power is resilient to the inclusion of neutral variants and noninformative external weights. We applied the proposed aGEw test to the Pancreatic Cancer Case–Control Consortium (discovery cohort of 3,585 cases and 3,482 controls) and the PanScan II genome‐wide association study data (replication cohort of 2,021 cases and 2,105 controls) with smoking as the exposure of interest. Two novel putative smoking‐related pancreatic cancer susceptibility genes, TRIP10 and KDM3A, were identified. The aGEw test is implemented in an R package aGE.
The Clinical Impact of CLIR Tools toward Rapid Resolution of Post-Newborn Screening Confirmatory Testing for X-Linked Adrenoleukodystrophy in California
Tang, Hao , Matteson, Jamie , Rinaldo, Piero, Tortorelli, Silvia , Currier, Robert J. , Sciortino, Stanley , Currier, Robert , Tortorelli, Silvia

Mayo Clinic

International Journal of Neonatal Screening | August 5, 2020 | Volume: 6 | Issue: 3 | Pages: 62

10.3390/ijns6030062 | PMID 33123639 Get It

Since the start of X-linked adrenoleukodystrophy (ALD) newborn screening in California, more than half of the diagnosed cases were found to have an ATP binding cassette subfamily D member 1 (ABCD1) gene variant of uncertain significance (VUS). To determine retrospectively the likelihood that these were true positive cases, we used a web-based post-analytical tool in Collaborative Laboratory Integrated Reports (CLIR). Confirmatory plasma very long-chain fatty-acids (VLCFA) profiles for ALD screen positive infant boys were run through the CLIR ALD tool. We compared the distribution by ABCD1 variant classification (pathogenic, likely pathogenic, VUS, and no variant) with the CLIR tool score interpretation (non-informative, possibly ALD, likely ALD, and very likely ALD) and the current case diagnosis. The study showed that CLIR tool positive interpretations were consistent with 100% of the pathogenic and likely pathogenic variants on the ABCD1 gene if a more conservative guideline was used. The tool interpretations were also consistent with screened cases that were determined to not have disease (our no-disorder group). The CLIR tool identified 19 diagnosed ALD cases with VUS to be potential false positives, representing a 40% reduction among all diagnosed ALD cases with VUS. The reduction could be extended to 65% if a more aggressive threshold was used. Identifying such preventable false positives could alleviate the follow-up burden for patients, their families, and California Special Care Centers.
Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee
Larson, Daniel P. , Akkari, Yassmine, Dyke, Daniel L. Van , Raca, Gordana , Gardner, Juli-Anne, Rehder, Catherine , Kaiser‐Rogers, Kathleen, Eagle, Penny, Yuhas, Jason, Kearney, Hutton M. , Conlin, Laura K. , Dolan, Michelle, Peterson, Jess F. , Van Dyke, Daniel L, Yuhas, Jason A, Kearney, Hutton, Peterson, Jess F , Gu, Jun , Toydemir, Reha M. , Tang, Guilin , Ketterling, Rhett P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 27, 2020 | Volume: 145 | Issue: 2 | Pages: 176-190

10.5858/arpa.2020-0089-cp | PMID 32886736 Get It

Context.— One goal of the joint College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee is to ensure the accurate detection and description of chromosomal abnormalities in both constitutional and neoplastic specimens, including hematologic neoplasms. Objective.— To report a 20-year performance summary (1999–2018) of conventional chromosome challenges focusing on hematologic neoplasms. Design.— A retrospective review was performed from 1999 through 2018 to identify karyotype challenges specifically addressing hematologic neoplasms. The overall performance of participants was examined to identify potential recurring errors of clinical significance. Results.— Of 288 total conventional chromosome challenges from 1999–2018, 87 (30.2%) were presented in the context of a hematologic neoplasm, based on the provided clinical history, specimen type, and/or chromosomal abnormalities. For these 87 hematologic neoplasm challenges, 91 individual cases were provided and graded on the basis of abnormality recognition and karyotype nomenclature (ISCN, International System for Human Cytogenomic [previously Cytogenetic] Nomenclature). Of the 91 cases, 89 (97.8%) and 87 (95.6%) exceeded the required 80% consensus for grading of abnormality recognition and correct karyotype nomenclature, respectively. The 2 cases (2 of 91; 2.2%) that failed to meet the 80% consensus for abnormality recognition had complex karyotypes. The 4 cases (4 of 91; 4.4%) that failed to meet the 80% consensus for correct karyotype nomenclature were the result of incorrect abnormality recognition (2 cases), missing brackets in the karyotype (1 case), and incorrect breakpoint designation (1 case). Conclusions.— This 20-year review demonstrates clinical cytogenetics laboratories have been and continue to be highly proficient in the detection and description of chromosomal abnormalities associated with hematologic neoplasms.
Association between chocolate consumption and risk of coronary artery disease: a systematic review and meta-analysis
Krittanawong, Chayakrit , Narasimhan, Bharat , Hahn, Joshua , Zhang, HongJu, Tang, W.H. Wilson , Farrell, Ann M, Tang, W H Wilson , Wang, Zhen , Virk, Hafeez Ul Hassan , Farrell, Ann

Mayo Clinic

European Journal of Preventive Cardiology | July 22, 2020 | Volume: 28 | Issue: 12 | Pages: e33-e35

10.1177/2047487320936787 | PMID 34647587 Get It

An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia
Ng, Kevin, Titus, Erron W. , Lieve, Krystien V.V. , Roston, Thomas M. , Mazzanti, Andrea , Deiter, Fred , Ingles, Jodie , Till, Jan , Robyns, Tomas , Connors, Sean P., Pang, B. , Bos, J. Martijn , Duffett, Stephen A. , Maltret, Alice , Green, Martin S. , Rutberg, Julie, Balaji, Seshadri , Cadrin‐Tourigny, Julia , Orland, Kate M. , Knight, Linda M., Brateng, Caitlin, Wu, Jeremy , Tang, Anthony , Skanes, Allan C. , Manlucu, Jaimie , January, Craig T., Collins, Kathryn K. , Maginot, Kathleen R., Fischbach, Peter , Etheridge, Susan P. , Eckhardt, Lee L. , Hamilton, Robert M. , Ackerman, Michael J. , Rosés‐Noguer, Ferran , Semsarian, Christopher , Jura, Natalia , Priori, Silvia G. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Deo, Rahul C. , Roberts, Jason D. , Eckhardt, Lee L , Bos, Johan M , Robyns, Tomas , Sanatani, Shubhayan , Hamilton, Robert , Rosés-Noguer, Ferran , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Ingles, Jodie , Priori, Silvia , Lieve, Krystien V , Denjoy, Isabelle , Connors, Sean P., Steinberg, Christian , Abrams, Dominic J. , Scheinman, Melvin M , Werf, Christian van der , Knight, Linda M., Healey, Jeff S. , Krahn, Andrew D. , Leenhardt, Antoine , Gollob, Michael H.

Mayo Clinic

Circulation | July 22, 2020 | Volume: 142 | Issue: 10 | Pages: 932-947

10.1161/circulationaha.120.045723 | PMID 32693635 Get It

Background: Genetic variants in calsequestrin-2 ( CASQ2 ) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2 -CPVT was sought through an international multicenter collaboration. Methods: Genotype-phenotype segregation in CASQ2 -CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. Results: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6–11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3–8.0; P =0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6–269.1; P <0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. Conclusions: This international multicenter study of CASQ2 -CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.
Noninvasive assessment of liver fibrosis in chronic hepatitis B carriers with sound touch elastography: study of surgical pathology specimens
Li, Jiawu , Ma, Lin , Xiang, Hongjin , He, Du , Lu, Changli, Tang, Lin , Chen, Shigao , Yang, Lulu , Luo, Yan

Mayo Clinic

Expert Review of Medical Devices | July 18, 2020 | Volume: 17 | Issue: 8 | Pages: 845-853

10.1080/17434440.2020.1798226 | PMID 32686517 Get It

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors
Hálfdánarson, Þorvarður R. , Tang, Laura , Bellizzi, Andrew M. , Bergsland, Emily K. , Halperin, Daniel M. , Eads, Jennifer R. , Singh, Simron , Metz, David C. , Naraev, Boris G., Reidy‐Lagunes, Diane , Howe, James R. , Pommier, Rodney F. , Menda, Yusuf , Chan, Jennifer A. , Halfdanarson, Thorvardur R , Bellizzi, Andrew M , Howe, James R , Menda, Yusuf , Strosberg, Jonathan , O’Dorisio, Thomas M. , Fishbein, Lauren , Hope, Thomas A. , Salem, Riad

Mayo Clinic

Pancreas | July 14, 2020 | Volume: 49 | Issue: 7 | Pages: 863-881

10.1097/mpa.0000000000001597 | PMID 32675783 Get It

AbstractThis article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection. The available literature was reviewed for each of the question and panel members voted on controversial topics, and the recommendations were included in a document circulated to all panel members for a final approval.
Increased cellular senescence in the murine and human stenotic kidney: Effect of mesenchymal stem cells
Kim, Seo Rin , Zou, Xiangyu , Puranik, Amrutesh S. , Abumoawad, Abdelrhman , Zhu, Xiangyang , Textor, Stephen C., Kirkland, James L. , Lerman, Lilach O. , Abumoawad, Abdelrhman M, Tchkonia, Tamara, Lerman, Lilach O , Puranik, Amrutesh S , Tang, Hui Jun , Hickson, LaTonya J. , Tchkonia, Tamar

Mayo Clinic

Journal of Cellular Physiology | July 13, 2020 | Volume: 236 | Issue: 2 | Pages: 1332-1344

10.1002/jcp.29940 | PMID 32657444 Get It

AbstractCell stress may give rise to insuperable growth arrest, which is defined as cellular senescence. Stenotic kidney (STK) ischemia and injury induced by renal artery stenosis (RAS) may be associated with cellular senescence. Mesenchymal stem cells (MSCs) decrease some forms of STK injury, but their ability to reverse senescence in RAS remains unknown. We hypothesized that RAS evokes STK senescence, which would be ameliorated by MSCs. Mice were studied after 4 weeks of RAS, RAS treated with adipose tissue‐derived MSCs 2 weeks earlier, or sham. STK senescence‐associated β‐galactosidase (SA‐β‐Gal) activity was measured. Protein and gene expression was used to assess senescence and the senescence‐associated secretory phenotype (SASP), and staining for renal fibrosis, inflammation, and capillary density. In addition, senescence was assessed as p16+ and p21+ urinary exosomes in patients with renovascular hypertension (RVH) without or 3 months after autologous adipose tissue‐derived MSC delivery, and in healthy volunteers (HV). In RAS mice, STK SA‐β‐Gal activity increased, and senescence and SASP marker expression was markedly elevated. MSCs improved renal function, fibrosis, inflammation, and capillary density, and attenuated SA‐β‐Gal activity, but most senescence and SASP levels remained unchanged. Congruently, in human RVH, p21+ urinary exosomes were elevated compared to HV, and only slightly improved by MSC, whereas p16+ exosomes remained unchanged. Therefore, RAS triggers renal senescence in both mice and human subjects. MSCs decrease renal injury, but only partly mitigate renal senescence. These observations support exploration of targeted senolytic therapy in RAS.
Mesenchymal Stem/Stromal Cells and their Extracellular Vesicle Progeny Decrease Injury in Poststenotic Swine Kidney Through Different Mechanisms
Zhao, Yu , Zhu, Xiangyang , Zhang, Lei , Ferguson, Christopher M. , Song, Turun , Conley, Sabena M., Krier, James D., Tang, Hui , Saadiq, Ishran M. , Jordan, Kyra L., Lerman, Lilach O. , Jiang, Kai , Saadiq, Ishran, Jiang, Kai, Lerman, Amir

Mayo Clinic

Stem Cells and Development | July 13, 2020 | Volume: 29 | Issue: 18 | Pages: 1190-1200

10.1089/scd.2020.0030 | PMID 32657229 Get It

Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure
Morris, Alanna A. , D’Souza, Melroy A. , Felker, G. Michael , Redfield, Margaret M. , Tang, W.H. Wilson , Butler, Javed , Tang, W H Wilson , Butler, Javed , Nayak, Aditi , Ko, Yi-An, D’Souza, Melroy, Testani, Jeffrey M.

Mayo Clinic

Circulation: Heart Failure | July 8, 2020 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.119.006827 | PMID 32635768 Get It

Background: Black patients have higher rates of hospitalization for acute heart failure than other race/ethnic groups. We sought to determine whether diuretic efficiency is associated with racial differences in risk for rehospitalization after acute heart failure. Methods: A post hoc analysis was performed on 721 subjects (age, 68±13 years; 22% black) enrolled in 3 acute heart failure clinical trials: ROSE-AHF (Renal Optimization Strategies Evaluation in Acute Heart Failure), DOSE-AHF (Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure), and CARRESS-HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure). Repeated-measures ANOVA was used to test for a race×time effect on measures of decongestion. Diuretic efficiency was calculated as net fluid balance per total furosemide equivalents. In a subset of subjects, Cox regression was used to examine the association between race and rehospitalization according to plasma renin activity (PRA). Results: Compared with nonblack patients, black patients were younger and more likely to have nonischemic heart failure. During the first 72 to 96 hours, there was greater fluid loss ( P =0.001), decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide; P =0.002), and lower levels of PRA ( P <0.0001) in black patients. Diuretic efficiency was higher in black than in nonblack patients (403 [interquartile range, 221–795] versus 325 [interquartile range, 154–698]; P =0.014). However, adjustment for baseline PRA attenuated the association between black race and diuretic efficiency. Over a median follow-up of 68 (interquartile range, 56–177) days, there was an increased risk of all-cause and heart failure–specific rehospitalization in nonblack patients with increasing levels of PRA, while the risk of rehospitalization was relatively constant across levels of PRA in black patients. Conclusions: Higher diuretic efficiency in black patients with acute heart failure may be related to racial differences in activity of the renin-angiotensin-aldosterone system.